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Background: Guidelines on hypertension management recommend adjusting therapeutic efforts in accordance
with global cardiovascular risk (CVR) rather than by blood pressure levels alone. However, this paradigm change
has not yet arrived in German General Practice. We have evaluated the effect of an educational outreach visit
with general practitioners (GPs), encouraging them to consider CVR in treatment decisions for patients with
hypertension.
Methods: Prospective cluster-randomised trial comprising 3443 patients with known hypertension treated by 87
GPs. Practices were randomly assigned to complex (A) or simple (B) intervention. Both groups received a guideline
by mail; group A also received complex peer intervention promoting the concept of global CVR. Clinical data were
collected at baseline and 6-9 months after intervention. Main outcome was improvement of calculated CVR in the
predefined subpopulation of patients with a high CVR (10-year mortality ≥5%), but no manifest cardiovascular disease.
Results: Adjusted for baseline the follow-up CVR were 13.1% (95% CI 12.6%-13.6%) (A) and 12.6% (95% CI 12.2%-13.1%)
(B) with a group difference (A vs. B) of 0.5% (-0.2%-1.1%), p = 0.179. The group difference was -0.05% in patients of GPs
familiar with global CVR and 1.1% in patients of GPs not familiar with with global CVR. However, this effect modification
was not significant (p = 0.165). Pooled over groups, the absolute CVR reduction from baseline was 1.0%, p < 0.001. The
ICC was 0.026 (p = 0.002). Hypertension control (BP <140/90 mmHg) improved in the same subpopulation from 38.1
to 45.9% in the complex intervention group, and from 35.6 to 46.5% in the simple intervention group, with adjusted
follow-up control rates of 46.7% (95% CI 40.4%-53.1%) (A) and 46.9% (95% CI 40.3%-53.5% (B) and an adjusted odds
ratio (A vs B) of 0.99 (95% CI 0.68-1.45), p = 0.966.
Conclusions: Our complex educational intervention, including a clinical outreach visit, had no significant effect on CVR
of patients with known hypertension at high risk compared to a simple postal intervention.
Trial registration: ISRCTN44478543.
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Arterial hypertension is an important risk factor for the
occurrence of cardiovascular disease (CVD). However,
recent scientific understanding [1-4] and subsequently the
published guidelines [5-8] recommend that the intensity
of therapeutic efforts should no longer follow set limit
levels, such as “<140/90 mm Hg”, but take individual CVR
into account: “treat risk, not risk factors” [2].
This paradigm change, although receiving broad scien-
tific consensus, has not fully reached health services re-
search and clinical practice. Many surveys continue to
report “hypertension control” rates without considering
CVR [8,9], and the new concept remains unfamiliar in
family practice [10,11]. Hypertension control in the rele-
vant target group with manifest CVD or otherwise high
CVR remains poor [12], despite improvements in some
countries [13,14]. A recent Cochrane review on interven-
tions used to improve control of blood pressure in pa-
tients with hypertension found that “none of the included
RCTs attempted to manage hypertension in the context of
overall cardiovascular risk”, concluding that “future stud-
ies need to be congruent with hypertension guidelines that
recommend treatment and control of blood pressure in
combination with multi-factorial risk reduction” [15].
If physicians are to consider global CVR before recom-
mending anti-hypertensive treatment, they need to as-
sess and discuss it with their patients. The use of CVR
calculators in the consultation may improve patient sat-
isfaction and involvement [16-18], although few physi-
cians seem to use them [19]. However, little is known
about the effects of this “double paradigm shift” [16]
toward global CVR and shared decision making on clin-
ical outcomes. Only a few intervention studies addressing
hypertension management in primary care with explicit
consideration of global cardiovascular risk have been pub-
lished [20], of which only one measured CVR before and
after the intervention [21].
The trial reported here evaluated the effect of a com-
plex intervention in German General Practice, including
an educational outreach visit, on global CVR of patients




We report a prospective non-blinded longitudinal cluster-
randomised intervention trial involving general practi-
tioners and their patients with known hypertension. The
trial tested the superiority of a complex (A) over a simple
(B) intervention at the physician (cluster) level, whereas
outcomes were measured as improvement of CVR at pa-
tient level.
The detailed protocol of CRISTOPH (cluster-rando-
mised intervention study to optimise the treatment ofpatients with hypertension) has already been published
[22], as has a secondary analysis of the baseline data [23].
The trial was registered at ISRCTN44478543.
Practices and participants
89 general practitioners (GPs) were recruited in 3 regions
close to the cities of Düsseldorf, Cologne and Aachen.
Each GP was asked to enrol a consecutive sample of 40
patients with a known diagnosis of hypertension from his
or her daily patient flow, regardless of the current cause
for consultation. Other inclusion criteria were age (40-75
years) and continuity of care by the GP over at least
6 months. Emergency cases and patients expected to die
within one year were excluded.
Ethical approval (No. 2715) was obtained from the
Ethics Committee of the medical faculty of the University
of Düsseldorf. Patient consent was deemed unnecessary
by the Committee since we use anonymous data routinely
collected by GPs.
Cluster randomisation
After enrolling the patients and recording of baseline data,
GPs were cluster-randomised into 2 groups, A (complex
intervention) and B (simple intervention). One GP (or one
group practice with 1-3 GPs) represents a cluster, whereas
the patients are the observation units.
To avoid the possibility that GPs familiar with the con-
cept of global CVR were accidentally over-represented in
either group, we asked them to estimate the CVR of each
patient enrolled. This estimate was compared with the re-
spective patients’ calculated CVR, and the GPs were di-
vided into 2 groups according to whether their estimate
was close to or far from the calculated CVR. ‘Close to’ was
assessed if the mean deviation of the estimated from the
calculated CVR was below 0.5% and the mean absolute
deviation was <0.75% (both values were near the median
for all GPs). Thus, 45 GPs were defined as familiar and 44
as not familiar with global CVR. The resulting strata were
used for a stratified randomization to balance the familiar-
ity between random groups. Because of the necessity to
randomise all GP’s working in group practices into the
same study group (A or B), stratified randomisation re-
sulted in a higher imbalance (47 in A and 42 in B) than
the otherwise expected 45 versus 44.
Baseline data and subgroups by CVR
A total of 3,523 patients were enrolled, the baseline data
being given in Table 1. There was no significant differ-
ence between groups A and B at baseline. 23% of all pa-
tients were reported to have a manifest cardiovascular
disease (CVD), 47.7% had a high CVR (SCORE ≥5%) with-
out manifest CVD, and 29.3% had a low CVR, defined by
a cardiovascular 10-year mortality (SCORE) of <5%, with-
out manifest CVD.
Table 1 Baseline information





Mean age (years) 63.8 ± 9.3 63.4 ± 9.1
No (%) female sex 993/1846 (53.8) 857/1672 (51.3)
No (%) of smokers 385/1809 (21.3) 300/1645 (18.2)
Mean BP systolic (mmHg) 137.8 ± 17.0 138.7 ± 16.9
Mean BP diastolic (mmHg) 81.5 ± 9.6 82.3 ± 9.2
Mean Total cholesterol (mg/dl) 216.0 ± 43.0 219.4 ± 44.8
No (%) with diabetes mellitus 623/1845 (33.8) 485/1671 (29.0)
No (%) renal failure 73/1841 (4.0) 56/1670 (3.4)
Mean 10-year risk of cardiovascular mortality 0.104 (±0.094) 0.099 (±0.088)
No (%) with manifest CVD (secondary prevention) 430/1755 (24.5) 340/1600 (21.3)
No (%) with ischemic heart disease 286/1845 (15.5) 236/1673 (14.1)
No (%) with cerebrovascular disease 107/1840 (5.8) 99/1672 (5.9)
No (%) peripheral artery disease 122/1841 (6.6) 87/1669 (5.29)
No (%) with no CVD (primary prevention) 1325/1755 (75.5) 1260/1600 (78.8)
No (%) with low CVR (10 year risk of cardiovascular mortality < 5%) 495/1755 (28.2) 488/1600 (30.5)
No (%) with high CVR (10 year risk of cardiovascular mortality≥ 5%) 830/1755 (47.3) 772/1600 (48.3)
Quantitative values are expressed as the mean ± SD.
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Implementation of clinical guidelines into professional
practice presents a major challenge [24]. While it is diffi-
cult to change professional behaviour overall, with only
small changes to be expected, complex interventions in-
cluding educational outreach visits may yield a sustain-
able and relevant effect than simple measures, such as
merely disseminating guidelines [25].
The assumption we made was that improvements in the
GPs’ knowledge about the concept of global CVR and case-
based training of their competence in using cardiovascular
risk tables would lead to improvement in their manage-
ment of CRV factors, particularly in patients at high risk.
Simple intervention
All participating physicians received by mail a written
manual (17 pages) we had specifically developed for GPs
on the basis of the ESC-Guidelines [6], and a set of 50
copies of the SCORE CVR tables, with a specifically de-
signed patient information text overleaf. There was an
accompanying letter encouraging the GPs to use these
materials for the management of their patients with ar-
terial hypertension.
Our concern was that the benefit of the complex, and
therefore more costly, intervention should be regarded
as relevant only if the effect could be demonstratedagainst a less complex cheaper intervention. Since passive
dissemination of guidelines has had little or no effect on rele-
vant clinical outcomes [26], this simple intervention probably
constituted a factual “usual care” control (B) group.
Complex intervention
For the GPs assigned to the complex (A) intervention
group, multi-faceted intervention was developed that in-
cluded, in addition to the written materials disseminated
by mail (cf simple intervention), a personal intervention
comprising an educational outreach visit by a peer (30-
45 min) and a feedback telephone call by the same peer
3 weeks later (5-10 min).
During the outreach visit, a peer and a GP discussed
the new concept on the basis of: (a) the mailed manual,
and (b) 3-4 suitable cases selected by the former from
this GP’s baseline data. The cases had to include at least
one patient with a history of CVD, and at least 2 patients
without such a history. Of the latter, one would be at low
risk (SCORE <5%), and one at high risk (≥5%). Discussion
of the GPs’ respective patient cases included feedback ele-
ments, which served as concrete examples to demonstrate
the paradigmatic changes of the CVR concept to the GP.
The GPs were also instructed how to use the SCORE cal-
culator of global CVR (print version), and were demon-
strated the patient information leaflet.
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to explore the GPs’ understanding, beliefs and attitudes
during the initial phase of the conversation in order to
tailor the concept’s message to him or her. Standardisa-
tion was facilitated by a dialogue draft for the outreach
visit, regular audit-meetings, and personal feedback from
a passive observer who attended the first 3 visits of each
peer. The complex intervention (A) included the follow-
ing elements:
a. Provision of a written manual (17 pages) and patient
information leaflets sent by mail to the GP (similar
to the simple intervention B).
b. Educational outreach visit of the GPs by peers,
including instruction on how to use the SCORE
CVR calculator.
c. Feedback telephone call 3-4 weeks after the outreach
visit.
The educational intervention was based on five key
messages:
1. Therapeutic decisions in the management of
hypertension should always be preceded by an
estimation of absolute CVR.
2. Within certain limits, there are no fixed targets for
blood pressure or cholesterol level. Potential risk
reductions by drug intake or life-style modification
depend on the absolute CVR before treatment.
3. All patients with hypertension should be encouraged
to improve or continue a healthy lifestyle. Drug
therapy is regarded beneficial in patients at high
CVR (SCORE ≥5%) or with manifest CVD.
4. There are often several options to reduce CVR. If
one option is barred (for example, because of
adverse patient preferences or drug side effects),
other options need to be considered.
5. Explaining individual CVR may enhance
communication between the physician and the
patient, providing the opportunity to invite the
patient to share in decision-making.
The GPs were not informed of the existence of 2 differ-
ent interventions, leaving them unaware of which inter-
vention group they belonged.
Data collection
Data collection procedures were the same in both groups.
We employed a self-developed paper documentation be-
cause of the limited extent and availability of routine com-
puterised data. At baseline, besides the sociodemographic
and history data given in Table 1 the actual blood pressure
reading (at enrolment) and the latest cholesterol measure-
ment (before enrolment) were noted.This study was designed with one follow-up data collec-
tion 6 to 9 months after the intervention that had been
conducted during a routine visit of the patient in the study
practice. Where available, the actual levels of blood pres-
sure and cholesterol were recorded by a practice. New
onset of diabetes mellitus, nephropathy or cardiovas-
cular events was also recorded by the GPs, and smok-
ing status updated.
Time frame and participant flow
Between January and August 2006, 89 GPs were recruited,
allowing the inclusion of 3,523 patients into the study.
After finishing the baseline data collection, 47 GP’s were
randomised to the complex intervention group A and 42
to the simple intervention group B.
During the intervention period (from June 2006 to
January 2007), 2 GPs and their corresponding study pa-
tients dropped out of the study. In the follow-up data col-
lection (from January to November 2007), the remaining
87 GPs had documented 3,443 patients. In 2,680 cases, full
data sets were available in order to compute 10-year CVR
before and after intervention according to the SCORE for-
mula. Practice and participant flow is given in Figure 1 as
the “study flow chart”.
Outcomes
We analysed changes in CVR, mean BP, total choles-
terol level, smoking rate hypertension control rate,
and CVR-lowering drug (ASS and statins). These were
calculated separately for 3 different subpopulations of
patients:
1. Patients with a history of manifest cardiovascular
disease (CVD).
2. Patients with high CVR (SCORE ≥5%), but no
history of CVD.
3. Patients with low CVR (SCORE < 5%), and no
history of CVD.
Global CVR of the latter 2 subpopulations has been cal-
culated employing the European SCORE formula, modi-
fied by factor 2 or 3 for men and women, respectively,
with diabetes [6].
Primary outcome of this trial was a reduction of calcu-
lated CVR in the subpopulation of patients at high CVR
(SCORE ≥5%) with no manifest CVD.
Sample size calculation
To demonstrate an effect of reducing mean calculated
CVR by 10% in the subgroup of patients with high CVR
(SCORE ≥ 5%, no history of CVD) with a power of 80%,
we calculated a necessary initial sample size of 2 × 51 re-
cruited GPs each enrolling 40 patients. We estimated a
GP drop out during the enrolment phase of 5%, a patient
Figure 1 Study flow chart.
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and follow-up of a further 5%, and a patient drop out be-
tween baseline and follow-up of 10% (resulting in 3146
patients enrolled by 92 GPs). Sample size calculation was
based on the assumption of a standard deviation of 0.44
for the CVR changes on the log-odds scale, an intra-class
correlation of 0.2, and a proportion of 40% high risk pa-
tients in the total sample, the latter being derived from a
pilot study of 330 patients cared for by 20 GPs. From
these assumptions, 2 × 816 patients were required for the
primary analysis in the high risk group.Statistical analysis
The analysis and the presentation of results follow the
CONSORT guidance on cluster randomized trials [27].
Primary analysis included all randomized patients of the
first (high CVR) subgroup with global CVR determina-
tions at baseline (ITT population). In case of missing
follow-up values, a LOCF (last-observation carried for-
ward) was imputed, i.e. the baseline determination was
imputed as follow-up determination. For the primary ana-
lysis, a 2-level random intercept model was fitted to
the data with follow-up CVR as outcome, random group
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CVR as covariate and, with patients nested in physicians
modeled as random effects. This hierarchical ANCOVA
model takes the correlation structure resulting from clus-
ter randomization into account and allows for differ-
ences between physicians in treatment effects. The
primary analysis used the fixed effects contrast test that
compares the mean follow-up CVR adjusted for baseline
CVR between random groups. We report the estimated
means with confidence limits, the group differences with
confidence limits and p and the intraclass correlation
coefficient (ICC) with corresponding p value. Effect
modification by CVR familiarity of GP was tested by add-
ing the corresponding interaction term to the hierarchical
model. The reported p value results from the max-
imum likelihood test that compares the models with
and without interaction term. If pre-post changes were
to be analyzed subsequently, this was done for the random
groups or for the total subpopulation with paired t tests
for continuous outcomes or McNemar tests for binary
outcomes.
As sensitivity analyses, calculations were repeated for
the complete cases population and for a dataset with miss-
ing values imputed by an EM algorithm.
Secondary analyses involved only the complete cases.
Analogous to the primary analysis, mixed models were
fitted separately for the secondary endpoints in groups
1, 2 and 3. If the outcome was binary, the hierarchical
ANCOVA model was replaced by a hierarchical logistic
regression model with the corresponding factor, covariate
and random part as in the ANCOVA models. As a post-
hoc analysis, the pooled statin intervention effect was cal-
culated across all types of patients.
Calculations used the last available versions of SPSS





Mean FU 95% CI Mean FU 95% C
CVR 13.0% 12.5%-13.6% 12.5% 11.9%
RR systolic [mmHg] 138.0 136.4-139.7 137.3 135.6-
RR diastolic [mmHg] 80.5 79.6-81.4 80.0 79.0-8
Control rate RR < 140/90 46.7% 40.4%-53.1% 46.9% 40.3%
Control rate RR < 160/95 86.8% 83.1%-90.6% 88.9% 85.4%
Cholesterol [mg/dl] 221.9 219.1-224.6 220.9 218.1-
Current smoker 12.0% 9.7%-14.4% 14.4% 11.9%
ASS 21.4% 19.1%-23.7% 23.9% 21.0%
Statins 23.3% 19.7%-26.9% 19.4% 15.8%
Outcomes at follow up in subpopulation at high CVR (10-year mortality ≥ 5%), but n
effects into account by use of a mixed model.Results
Baseline information is presented in Table 1. The out-
comes of the study are reported separately for the 3
CVR subpopulations.
The primary analysis was in the ITT subpopulation of
patients with high CVR (SCORE ≥ 5%, no history of CVD).
The raw mean calculated CVR changed from 14.3% (A)
and 13.4% (B) at baseline to 13.4% (A) and 12.3% (B) at
follow-up. Adjusted for baseline the follow-up CVR were
13.1% (95% CI 12.6%-13.6%) (A) and 12.6% (95% CI
12.2%-13.1%) (B) with a group difference (A vs. B) of 0.5%
(-0.2%-1.1%), p = 0.179. The group difference was -0.05%
in patients of GPs familiar with global CVR and 1.1%
in patients of GPs not familiar with with global CVR.
However, this effect modification was not significant
(p = 0.165). Pooled over groups, the absolute CVR reduc-
tion from baseline was 1.0%, p < 0.001. The ICC was 0.026
(p = 0.002).
Sensitivity analysis with EM imputation yielded similar
results. Sensitivity analysis with complete cases confirmed
these results (-1.0% vs. -1.3%, cf. Table 2).
Similarly, hypertension control (BP <140/90 mmHg)
improved in the same subpopulation from 38.1 to 45.9%
in the complex intervention group, and from 35.6 to
46.5% in the simple intervention group, with adjusted
follow-up control rates of 46.7% (95% CI 40.4%-53.1%)
(A) and 46.9% (95% CI 40.3%-53.5% (B) and an adjusted
odds ratio (A vs B) of 0.99 (95% CI 0.68-1.45), p = 0.966
(Table 2). Pooled over groups, the increase was 9.4%
(p < 0.001).
In the complex intervention group, the reported smok-
ing rate decreased from 19.4 to 13.5% compared to a
reduction in the simple intervention group from 15.6
to 13.6%. The adjusted odds ratio was not significant
(Table 2).on B A vs. B
I Difference/Odds ratio 95% CI p ICC p
-13.1% Δ = 0.5% -0.3%-1.3% 0.197 0.029 0.004
139.1 Δ = 0.7 -1.7-3.1 0.563 0.082 <0.001
0.9 Δ = 0.5 -0.8-1.8 0.461 0.078 <0.001
-53.5% OR = 0.99 0.68-1.45 0.966 0.128 <0.001
-92.3% OR = 0.82 0.51-1.31 0.405 0.141 <0.001
223.7 Δ = 1.0 -3.0-4.93 0.634 0.015 0.085
-17.0% OR = 0.71 0.44-1.16 0.171 0.093 0.019
-26.8% OR = 0.67 0.37-1.19 0.172 0.206 <0.001
-23.0% OR = 1.52 0.89-2.62 0.128 0.206 <0.001
o manifest CVD (complete cases), adjusted for baseline and taking cluster
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calculated 10-year (CRV) increased slightly during the
intervention period (+0.4% vs. +0.3%), with no signifi-
cant difference between the 2 groups (Table 3). Changes
in hypertension control and smoking rates were small
and not significant (data not shown).
In the subpopulation of patients with manifest CVD,
little or no effects were detected in mean blood pressure,
hypertension control and cholesterol level. In the com-
plex intervention group, the smoking rate fell signifi-
cantly from 20.8 to 15.3% compared to a small change
in the control group from 23.3 to 20.8% (Table 4). Nei-
ther of these differences in smoking rates was statisti-
cally significant.
With regard to prescription rates of statins, interven-
tion effects were much higher in the group of patients
with manifest CVD (OR = 2.63, p = 0.005; Table 4). In
patients with low CVR, significance of a moderate inter-
vention effect was just missed (OR = 1,90, p = 0,053;
Table 3), and in patients with high CVR, there was no
intervention effect (Table 2). However, the differences
between the intervention effects of CVR groups were
not significant (p = 0.0639). Pooled over groups, the
follow-up statin prescription rates were 30.7% (95% CI
27.2%-34.2%) (A) and 24.1% (95% CI 20.5%-27.7%) (B)
with an odds ratio (A vs. B) of 1.9 (1.2-3.1), p = 0.010,
ICC = 0.225, p < 0.001. Prescription rates of ASS did not
differ between groups (Tables 2, 3 and 4).
ICCs were mostly significant. Lowest in CVR, they were
high in medication, control rate and smoking (Tables 2, 3
and 4) in each of the subgroups.
Discussion
Main findings
While the targeted subpopulation of patients with high
CVR (SCORE ≥ 5%, but no manifest CVD) did show a





Mean FU 95% CI Mean FU 95% C
CVR 2.9% 2.7%-3.1% 2.7% 2.5%-2
RR systolic [mmHg] 134.0 132.1-135.9 134.3 132.3-
RR diastolic [mmHg] 80.9 79.9-82.0 80.7 79.7-8
Control rate RR < 140/90 58.1% 51.3%-64.8% 54.0% 47.1%
Control rate RR < 160/95 90.2% 86.8%-93.6% 90.7% 87.4%
Cholesterol [mg/dl] 216.6 213.0-220.1 219.3 215.7-
Current smoker 16.2% 12.5%-20.0% 16.4% 12.5%
ASS 9.0% 7.0%-10.9% 9.2% 7.3%-1
Statins 18.1% 14.6%-21.6% 13.5% 10.2%
Outcomes at follow up in subpopulation at low CVR (10-year mortality < 5%) with n
effects into account by use of a mixed model.our complex (A) intervention offered no additional ef-
fects on CVR reduction compared with the simple (B)
intervention. There was, however, a large and significant
intervention effect on statin prescription rates in pa-
tients with manifest CVD.
Interpretation of the results
The fact that our complex intervention did not have the
intended greater effect than the simple (postal) interven-
tion has several possible explanations relating to (i) the de-
sign of the interventions, (ii) other aspects of the study
design, and (iii) the participating physicians and patients.
First, despite its complexity and strengths, our com-
plex intervention may have been insufficient, especially
in view of the deeply rooted beliefs and routines of GPs.
Thus it needs to be modified if consideration of global
CVR (and subsequently shared decision making in this
area) replaces single risk factor management in the minds
of doctors and patients.
Second, the observation period could also have been
too short for a change in calculated CVR to occur, al-
though we do not believe that the observed effect would
have increased with time without further boosting of the
intervention.
Third, it may be that patients were reluctant to comply
with additional treatment efforts, and/or that the physi-
cians were eventually not convinced by the new concept
and unwilling to change their routines. On the level of
GPs, familiarity with the concept of global CVR may
have affected the intervention effect. Although the inter-
action test was not significant, the results suggest that the
intervention might have been effective in a group of GPs
not familiar with the concept of CVR. However, we had
not taken into account stratification of GPs according to
CVR knowledge for the estimation of the intervention ef-
fect, and the power of the study was insufficient to demon-
strate an intervention effect in a specific subgroup. Thus,on B A vs. B
I Difference/Odds ratio 95% CI p ICC p
.9% Δ = 0.2% -0.1%-0.5% 0.282 0.032 0.043
136.2 Δ = -0.2 -2.9-2.5 0.866 0.097 <0.001
1.8 Δ = 0.2 -1.3-1.7 0.798 0.063 <0.001
-60.9% OR = 1.19 0.78-1.82 0.411 0.098 <0.001
-94.0% OR = 0.94 0.55-1.62 0.830 0.051 0.205
222.8 Δ = -2.7 -7.7-2.3 0.294 0.021 0.103
-20.3% OR = 0.98 0.48-1.99 0.948 0.240 <0.001
1.2% OR = 0.89 0.32-2.43 0.815 0.318 0.001
-16.7% OR = 1.89 0.98-3.62 0.056 0.150 0.010
o manifest CVD (complete cases), adjusted for baseline and taking cluster






Mean FU 95% CI Mean FU 95% CI Difference/Odds ratio 95% CI p ICC p
RR systolic [mmHg] 134.3 132.5-136.1 133.8 131.8-135.7 Δ = 0.5 -2.2-3.2 0.698 0.033 0.080
RR diastolic [mmHg] 78.1 77.0-79.2 79.1 77.9-80.2 Δ = -1.0 -2.5-0.6 0.243 0.048 0.020
Control rate RR < 140/90 59.2% 52.7%-65.7% 56.9% 49.9%-63.8% OR = 1.11 0.73-1.70 0.632 0.076 0.015
Control rate RR < 160/95 90.2% 86.4%-93.9% 88.9% 84.7%-93.1% OR = 1.15 0.66-1.99 0.623 0.037 0.280
Cholesterol [mg/dl] 197.8 194.1-201.6 199.8 195.8-203.9 Δ = -2.0 -7.6-3.6 0.482 0.000 1.000
Current smoker 15.2% 11.2%-19.1% 19.2% 15.1%-23.2% OR = 0.57 0.26-1.26 0.163 0.258 0.005
ASS 73.0% 69.2%-76.7% 73.3% 69.3%-77.2% OR = 0.96 0.46-2.01 0.917 0.230 <0.001
Statins 64.1% 57.2%-71.0% 48.2% 39.7%-56.7% OR = 2.64 1.35-5.16 0.005 0.280 <0.001
Outcomes at follow up in subpopulation at high CVR (10-year mortality ≥ 5%), but no manifest CVD (complete cases), adjusted for baseline and taking cluster
effects into account by use of a mixed model.
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would be required.
While there was no group difference, both groups showed
a significant reduction of CVR. This may have external
and/or internal causes: External causes or secular trends
include the introduction of disease management programs
for coronary heart disease and diabetes mellitus in
Germany in 2002, both affecting primary care and setting
incentives to improve CVR factor management. Also, the
concept of considering global CVR is a subject directed at
primary care physicians in some CME programs. Conceiv-
able internal causes comprise: (1) an equally strong effect
of both the complex (A) and simple (B) (postal) inter-
vention; (2) an increased awareness for reducing CVR fac-
tors in both the simple and complex intervention group
(Hawthorne effect) at the level of GPs and patients; (3) a
regression to the mean effect of our baseline and follow-
up measurements of both blood pressure and cholesterol;
and (4) a reporting bias on the side of the physicians
participating in the study in the sense of social expect-
ancy. This study yielded no evidence for either of these ex-
planations, but we believe that both the secular trend and
an increased unspecific attention on the side of the par-
ticipating physicians could account for much of the ob-
served effect.
Among the secondary outcomes, we did find a large
and significant intervention effect on statin prescription
rates in patients with manifest CVD, and a moderate
intervention effect that just missed significance in pa-
tients with low CVR, but no such effect in patients with
high CVR. The increased statin prescription rate in pa-
tients with manifest CVR is congruent with our recom-
mendation to rigorously lower CVR in these patients, and
thus seems in line with our complex (peer) intervention.
Perhaps this particular, straightforward (and familiar) com-
ponent of the intervention message was received by the
GPs most strongly. On the other hand, the (albeit just not
significant) moderate intensification of statin treatment inpatients with low CVR, and the absence of a group differ-
ence in statin prescriptions for patients with high CVR do
not add up to a comprehensible effect in the sense of our
intervention with regard to evidence-based treatment in
primary prevention, nor can we provide an alternative
explanation. The significant increase of statin prescrip-
tions in the pooled analysis suggests an increase of general
awareness of GPs concerning other cardiovascular risk
factors apart from blood pressure.
Finally, intraclass (intracluster) correlations (ICC) are
a measure of the variability between patients of different
GPs in relation to the variability of all patients. The high
ICC values seen for ASS and Statin reflects the dependency
introduced by the GP of prescribing it in most patients or
not prescribing it in any. However, with considerable vari-
ability between GPs in medication rates, hypertension con-
trol or smoking, the variability with CVR was very small in
both groups. It seems that the GPs of both groups go dif-
ferent ways in treating their patients, but agree in the goal
of CVR reduction in patients with high CVR.
Study findings in the context of other research
Traditionally, trials aimed at better management of arterial
hypertension are designed to improve blood pressure con-
trol, regardless of global cardiovascular risk [26,28]. There
are few papers available on the implementation of the
concept of global CVR in general, and of the use of car-
diovascular risk tables in particular, in the management of
arterial hypertension in the family-practice setting [15,20].
Few intervention studies have addressed hypertension
management in general practice that explicitly consider
global cardiovascular risk, and to our knowledge ours is
the first to be designed to primarily demonstrate a change
in calculated CVR.
One study, however, did calculate CVR before and after
the intervention as a secondary outcome; it found, like
ours, a small positive effect of both a simple and a com-
plex intervention, i.e. patient encouragement to change
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ment strategy, but no superiority of the complex inter-
vention [29]. A second study found positive effects of
using decision-aids - such as electronic or paper-based
CVR calculators facilitating shared decision-making be-
tween physicians and patients on patients’ satisfaction and
involvement - without negative effects on the calculated
CVR [16].
An intervention trial, including the training of physi-
cians in using a guideline and a decision support tool,
did not have the intended effect on GP performance, or
patients’ self-reported lifestyle and risk-perception [21].
The authors suggest that improvements in the manage-
ment of global CVR may have positive effects especially
in high risk patients who were not included in their
study. However, our study that included high risk pa-
tients (albeit in a different setting) does not confirm this
assumption.
Thus, while there is a strong scientific consensus that
the concept of treating cardiovascular risk rather than
single risk factors ought to be implemented in primary
care, including greater patient involvement and shared
decision-making, there is very little understanding of
how this could be undertaken and little evidence of suc-
cessful models.
Strengths and weaknesses of the study
The prominent strengths of this study include the high
number of participating primary care physicians and pa-
tients, and the cluster-randomized design that minimizes
the risk of selection bias at the level of physicians. The
multifaceted and thorough design of the complex peer-
intervention is also a strength, even if eventually it proved
ineffective.
Our study has also methodological limitations. The se-
lected regions and GPs were chosen for convenience,
which means that the results may not be fully represen-
tative of all German GPs. Despite our careful design, we
cannot exclude a selection bias at the patient level, pos-
sibly due to non-adherence to the rules of consecutive
patient enrolment on the side of the physicians. Further-
more, there could be a Hawthorne effect, i.e. that taking
part in a study can be a relevant intervention itself both
at the level of patients and GPs. This is a principle meth-
odological bias of interventions in healthcare research.
Another possible limitation lies in our decision to
compare the complex intervention not with usual care, but
with a simple intervention as the control group. This is
due to our pre-condition that the benefit of the complex,
and therefore costly, intervention should only be found
relevant if the benefit can be demonstrated against a less
complex, cheaper intervention. In many GP settings, how-
ever, our simple intervention comes close to usual care, as
guidelines are often posted to GPs. Systematic reviews ofinterventions to change professional practice show that
passive dissemination of information has little or no effect
on professional behavior [26,30].
Finally, our analysis does not take into account the
variability of follow-up-time (6 versus 9 months), and we
cannot tell whether duration of follow-up was associated
with any of the outcomes. Follow-up at 6 and 9 months
occurred only at GP level, not at patient level, so the follow
up data sets reflect cumulated, undated changes of medica-
tion, BP-levels, cholesterol-levels, smoking status etc. dur-
ing the observation period of 6 or 9 months. Therefore, an
analysis would not yield reliable results.
Conclusions
Treating patients with arterial hypertension according to
their global CVR rather than to set value limits is a ne-
cessary change of paradigm in family practice. Few exist-
ing intervention trials have been able to demonstrate
marked effects, and our study being the first designed to
measure the effect of an intervention of physician peer-
education on calculated patient CVR is no exception.
We conclude that our approach to implementing the
concept of global CVR into primary care was probably
not comprehensive and sufficiently sustainable to change
deep-rooted traditional risk factor treatment, which is in
accordance to the results of our embedded qualitative
study [31]. Given that the concept of global CVR implies
increased patient participation in treatment decisions, fu-
ture research should identify outcome parameters that do
take into account the informed choice of patients, even if
the latter might not lead to a lower CVR.
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